Points to consider in the development of seed stocks of
pluripotent stem cells for clinical applications: International
Stem Cell Banking Initiative (ISCBI)

J 2015

Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)

ANDREWS, P.W., D. BAKER, N. BENVINISTY, B. MIRANDA, K. BRUCE et. al.

Basic information

Original name

Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)

Authors

ANDREWS, P.W. (826 United Kingdom of Great Britain and Northern Ireland), D. BAKER (826 United Kingdom of Great Britain and Northern Ireland), N. BENVINISTY (376 Israel), B. MIRANDA (724 Spain), K. BRUCE (826 United Kingdom of Great Britain and Northern Ireland), O. BRUSTLE (276 Germany), M. CHOI (410 Republic of Korea), Y.M. CHOI (410 Republic of Korea), J.M. CROOK (36 Australia), P.A. de SOUSA (826 United Kingdom of Great Britain and Northern Ireland), Petr DVOŘÁK (203 Czech Republic, guarantor, belonging to the institution), C. FREUND (528 Netherlands), M. FIRPO (840 United States of America), M.K. FURUE (392 Japan), P. GOKHALE (826 United Kingdom of Great Britain and Northern Ireland), H.Y. HA (410 Republic of Korea), E. HAN (410 Republic of Korea), S. HAUPT (276 Germany), L. HEALY (826 United Kingdom of Great Britain and Northern Ireland), D.J. HEI (840 United States of America), O. HOVATTA (752 Sweden), C. HUNT (826 United Kingdom of Great Britain and Northern Ireland), S.M. HWANG (158 Taiwan), M.S. INAMDAR (356 India), R.M. ISASI (124 Canada), M. JACONI (756 Switzerland), V. JEKERLE (826 United Kingdom of Great Britain and Northern Ireland), P. KAMTHORN (764 Thailand), M.C. KIBBEY (840 United States of America), I. KNEZEVIC (756 Switzerland), B.B. KNOWLES (764 Thailand), S.K. KOO (410 Republic of Korea), Y. LAABI (250 France), L. LEOPOLDO (724 Spain), P. LIU (826 United Kingdom of Great Britain and Northern Ireland), G.P. LOMAX (840 United States of America), J.F. LORING (840 United States of America), T.E. LUDWIG (840 United States of America), K. MONTGOMERY (840 United States of America), C. MUMMERY (528 Netherlands), A. NAGY (124 Canada), Y. NAKAMURA (392 Japan), N. NAKATSUJI (392 Japan), S. OH (702 Singapore), S.K. OH (410 Republic of Korea), T. OTONKOSKI (246 Finland), M. PERA (840 United States of America), M. PESCHANSKI (250 France), P. PRANKE (76 Brazil), K.M. RAJALA (246 Finland), M. RAO (840 United States of America), R. RUTTACHUK (764 Thailand), B. REUBINOFF (376 Israel), L. RICCO (724 Spain), H. ROOKE (840 United States of America), D. SIPP (840 United States of America), G.N. STACEY (826 United Kingdom of Great Britain and Northern Ireland), H. SUEMORI (392 Japan), T.A. TAKAHASHI (392 Japan), K. TAKADA (392 Japan), S. TALIB (840 United States of America), S. TANNENBAUM (376 Israel), B.Z. YUAN (156 China), F. ZENG (156 China) and Q. ZHOU (156 China)

Edition

REGENERATIVE MEDICINE, LONDON, FUTURE MEDICINE LTD, 2015, 1746-0751

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

Genetics and molecular biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.602

RIV identification code

RIV/00216224:14110/15:00083494

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2217/RME.14.93

UT WoS

000349681900001

Keywords in English

COPY NUMBER; MOLECULAR CYTOGENETICS; GENOMIC STABILITY; GENE-EXPRESSION; LINES; CULTURE; CRYOPRESERVATION; MUTATIONS; TERATOCARCINOMAS; STANDARDIZATION

Abstract

V originále

In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications. The term ‘seed stock’ is used here to describe those cryopreserved stocks of cells established early in the passage history of a pluripotent stem cell line in the lab that derived the line or a stem cell bank, hereafter called the ‘repository’.

Citovat

ANDREWS, P.W., D. BAKER, N. BENVINISTY, B. MIRANDA, K. BRUCE, O. BRUSTLE, M. CHOI, Y.M. CHOI, J.M. CROOK, P.A. de SOUSA, Petr DVOŘÁK, C. FREUND, M. FIRPO, M.K. FURUE, P. GOKHALE, H.Y. HA, E. HAN, S. HAUPT, L. HEALY, D.J. HEI, O. HOVATTA, C. HUNT, S.M. HWANG, M.S. INAMDAR, R.M. ISASI, M. JACONI, V. JEKERLE, P. KAMTHORN, M.C. KIBBEY, I. KNEZEVIC, B.B. KNOWLES, S.K. KOO, Y. LAABI, L. LEOPOLDO, P. LIU, G.P. LOMAX, J.F. LORING, T.E. LUDWIG, K. MONTGOMERY, C. MUMMERY, A. NAGY, Y. NAKAMURA, N. NAKATSUJI, S. OH, S.K. OH, T. OTONKOSKI, M. PERA, M. PESCHANSKI, P. PRANKE, K.M. RAJALA, M. RAO, R. RUTTACHUK, B. REUBINOFF, L. RICCO, H. ROOKE, D. SIPP, G.N. STACEY, H. SUEMORI, T.A. TAKAHASHI, K. TAKADA, S. TALIB, S. TANNENBAUM, B.Z. YUAN, F. ZENG and Q. ZHOU. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). REGENERATIVE MEDICINE. LONDON: FUTURE MEDICINE LTD, 2015, vol. 10, No 2, p. 1-44. ISSN 1746-0751. Available from: https://dx.doi.org/10.2217/RME.14.93.

@article{1307860,
   author = {Andrews, P.W. and Baker, D. and Benvinisty, N. and Miranda, B. and Bruce, K. and Brustle, O. and Choi, M. and Choi, Y.M. and Crook, J.M. and Sousa, P.A. de and Dvořák, Petr and Freund, C. and Firpo, M. and Furue, M.K. and Gokhale, P. and Ha, H.Y. and Han, E. and Haupt, S. and Healy, L. and Hei, D.J. and Hovatta, O. and Hunt, C. and Hwang, S.M. and Inamdar, M.S. and Isasi, R.M. and Jaconi, M. and Jekerle, V. and Kamthorn, P. and Kibbey, M.C. and Knezevic, I. and Knowles, B.B. and Koo, S.K. and Laabi, Y. and Leopoldo, L. and Liu, P. and Lomax, G.P. and Loring, J.F. and Ludwig, T.E. and Montgomery, K. and Mummery, C. and Nagy, A. and Nakamura, Y. and Nakatsuji, N. and Oh, S. and Oh, S.K. and Otonkoski, T. and Pera, M. and Peschanski, M. and Pranke, P. and Rajala, K.M. and Rao, M. and Ruttachuk, R. and Reubinoff, B. and Ricco, L. and Rooke, H. and Sipp, D. and Stacey, G.N. and Suemori, H. and Takahashi, T.A. and Takada, K. and Talib, S. and Tannenbaum, S. and Yuan, B.Z. and Zeng, F. and Zhou, Q.},
   article_location = {LONDON},
   article_number = {2},
   doi = {http://dx.doi.org/10.2217/RME.14.93},
   keywords = {COPY NUMBER; MOLECULAR CYTOGENETICS; GENOMIC STABILITY; GENE-EXPRESSION; LINES; CULTURE; CRYOPRESERVATION; MUTATIONS; TERATOCARCINOMAS; STANDARDIZATION},
   language = {eng},
   issn = {1746-0751},
   journal = {REGENERATIVE MEDICINE},
   title = {Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)},
   volume = {10},
   year = {2015}
}

TY  - JOUR
ID  - 1307860
AU  - Andrews, P.W. - Baker, D. - Benvinisty, N. - Miranda, B. - Bruce, K. - Brustle, O. - Choi, M. - Choi, Y.M. - Crook, J.M. - Sousa, P.A. de - Dvořák, Petr - Freund, C. - Firpo, M. - Furue, M.K. - Gokhale, P. - Ha, H.Y. - Han, E. - Haupt, S. - Healy, L. - Hei, D.J. - Hovatta, O. - Hunt, C. - Hwang, S.M. - Inamdar, M.S. - Isasi, R.M. - Jaconi, M. - Jekerle, V. - Kamthorn, P. - Kibbey, M.C. - Knezevic, I. - Knowles, B.B. - Koo, S.K. - Laabi, Y. - Leopoldo, L. - Liu, P. - Lomax, G.P. - Loring, J.F. - Ludwig, T.E. - Montgomery, K. - Mummery, C. - Nagy, A. - Nakamura, Y. - Nakatsuji, N. - Oh, S. - Oh, S.K. - Otonkoski, T. - Pera, M. - Peschanski, M. - Pranke, P. - Rajala, K.M. - Rao, M. - Ruttachuk, R. - Reubinoff, B. - Ricco, L. - Rooke, H. - Sipp, D. - Stacey, G.N. - Suemori, H. - Takahashi, T.A. - Takada, K. - Talib, S. - Tannenbaum, S. - Yuan, B.Z. - Zeng, F. - Zhou, Q.
PY  - 2015
TI  - Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)
JF  - REGENERATIVE MEDICINE
VL  - 10
IS  - 2
SP  - 1-44
EP  - 1-44
PB  - FUTURE MEDICINE LTD
SN  - 17460751
KW  - COPY NUMBER
KW  - MOLECULAR CYTOGENETICS
KW  - GENOMIC STABILITY
KW  - GENE-EXPRESSION
KW  - LINES
KW  - CULTURE
KW  - CRYOPRESERVATION
KW  - MUTATIONS
KW  - TERATOCARCINOMAS
KW  - STANDARDIZATION
N2  - In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications. The term ‘seed stock’ is used here to describe those cryopreserved stocks of cells established early in the passage history of a pluripotent stem cell line in the lab that derived the line or a stem cell bank, hereafter called the ‘repository’.
ER  -

ANDREWS, P.W., D. BAKER, N. BENVINISTY, B. MIRANDA, K. BRUCE, O. BRUSTLE, M. CHOI, Y.M. CHOI, J.M. CROOK, P.A. de SOUSA, Petr DVOŘÁK, C. FREUND, M. FIRPO, M.K. FURUE, P. GOKHALE, H.Y. HA, E. HAN, S. HAUPT, L. HEALY, D.J. HEI, O. HOVATTA, C. HUNT, S.M. HWANG, M.S. INAMDAR, R.M. ISASI, M. JACONI, V. JEKERLE, P. KAMTHORN, M.C. KIBBEY, I. KNEZEVIC, B.B. KNOWLES, S.K. KOO, Y. LAABI, L. LEOPOLDO, P. LIU, G.P. LOMAX, J.F. LORING, T.E. LUDWIG, K. MONTGOMERY, C. MUMMERY, A. NAGY, Y. NAKAMURA, N. NAKATSUJI, S. OH, S.K. OH, T. OTONKOSKI, M. PERA, M. PESCHANSKI, P. PRANKE, K.M. RAJALA, M. RAO, R. RUTTACHUK, B. REUBINOFF, L. RICCO, H. ROOKE, D. SIPP, G.N. STACEY, H. SUEMORI, T.A. TAKAHASHI, K. TAKADA, S. TALIB, S. TANNENBAUM, B.Z. YUAN, F. ZENG and Q. ZHOU. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). \textit{REGENERATIVE MEDICINE}. LONDON: FUTURE MEDICINE LTD, 2015, vol.~10, No~2, p.~1-44. ISSN~1746-0751. Available from: https://dx.doi.org/10.2217/RME.14.93.

Detailed Information on Publication Record